Side effects after first and second doses of Covid-19 vaccine among health care providers in tertiary care hospital

Preeti Singh 1 * , Ruchi Choudhary 1, Prithpal Singh Matreja 1 * , Shilpa Patrick 1, Devesh Kumar 2, V K Singh 3
More Detail
1 Department of Pharmacology, Teerthanker Mahaveer Medical College and Research Center, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India
2 Department of Physiology, State Medical College and Allied Pt Ram Prasad Bismil Memorial Hospital, Dharnipur Jignera, Shahjahanpur, Uttar Pradesh, India
3 Department of General Medicine, Teerthanker Mahaveer Medical College and Research Center, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India
* Corresponding Author
J CLIN MED KAZ, Volume 20, Issue 4, pp. 49-53. https://doi.org/10.23950/jcmk/13528
OPEN ACCESS 635 Views 531 Downloads
Download Full Text (PDF)

ABSTRACT

Background: Acceptance of Covid-19 vaccination among the general population is one topic that has been discussed worldwide. Large number of doses of vaccine has been administered throughout the world, but, concerns about safety of Covid-19 vaccination still persists. There have been reports of adverse effects with Covid-19 vaccination which are mild and resolve spontaneously. This study was done to evaluate the side effects after first and second doses of Covid-19 vaccine among health care providers in tertiary care hospital.
Material and methods: This cross-sectional, questionnaire based study was done among health care workers after first and second dose of vaccine in Teerthanker Mahaveer Medical College & Research Center, Moradabad, India between January 2021 to July 2021. In this survey, post Covid-19 vaccination questionnaire was designed using Google Forms and was shared to vaccinated participants through social media and mail. Snowball sampling method was used for gathering a total of 485 responses. Informed consent was obtained from all research participants and the study was approved by the Institutional Review Board (IRB)
Results: The respondents were health care professionals which included Physician, Surgeons, and Other Health Care Workers.  The most common adverse effects reported after both doses of vaccination were fever, chills and rigor, headache, myalgia, malaise and pain at site of injection. The results showed that 65% (n=338) of participants had mild symptoms like headache, fever, pain at injection site, malaise, myalgia, dizziness, nausea and vomiting after first dose of vaccination. In comparison 39% (n=190) of participants reported mild symptoms after the administration of second dose of vaccination. A total of 63% (n=330) and 41% (n=197) participants took medication for relief of symptoms during post-vaccination period after the first and second dose of vaccine with slight female preponderance.
Conclusion: The most prevalent adverse effects following vaccination were nausea and vomiting, headache, dizziness, fever, chills, fatigue, including pain, redness and swelling at the injection site with more female preponderance. The adverse effect encountered were higher in number after the first dose of vaccination.
Keywords: Vaccination, adverse effects, Covid-19, health care workers.

CITATION

Singh P, Choudhary R, Matreja PS, Patrick S, Kumar D, Singh VK. Side effects after first and second doses of Covid-19 vaccine among health care providers in tertiary care hospital. J CLIN MED KAZ. 2023;20(4):49-53. https://doi.org/10.23950/jcmk/13528

REFERENCES

  • Holder J. Tracking coronavirus vaccinations around the world. The New York Times. 2021.
  • Kirzinger A, Kearney A, Hamel L, Brodie M. KFF/The Washington Post Frontline Health Care Workers Survey. 2021.
  • Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et.al. for the COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. https://doi.org/10.1056/NEJMoa2035389
  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et.al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-15. https://doi.org/10.1056/NEJMoa2034577
  • Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et.al.; Oxford COVID-19 Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
  • Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et.al.; ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2. S vaccine against COVID-19. N Engl J Med. 2021;384:2187-201. https://doi.org/10.1056/NEJMoa2101544
  • CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51. https://doi.org/10.15585/mmwr.mm7002e1
  • Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers TR, et.al. First month of COVID-19 vaccine safety monitoring-United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(8):283-88. https://doi.org/10.15585/mmwr.mm7008e3
  • Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, et.al. Safety monitoring of the Janssen (Johnson and Johnson) COVID-19 vaccine -United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):680-4. https://doi.org/10.15585/mmwr.mm7018e2
  • Shimabukuro T. CDC COVID-19 Vaccine Task Force: Vaccine Safety Team. COVID-19 vaccine safety update. 2021.
  • Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et.al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390-9. https://doi.org/10.1001/jama.2021.15072
  • Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et.al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21:939-49. https://doi.org/10.1016/S1473-3099(21)00224-3
  • Omeish H, Najadat A, Al-Azzam S, Tarabin N, Hameed AA, Al-Gallab N, et.al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum Vaccin Immunother. 2022;18(1):1981086. https://doi.org/10.1080/21645515.2021.1981086
  • Filippatos F, Tatsi EB, Dellis C, Dessypris N, Syriopoulou V, Michos A. Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers. Hum Vaccin Immunother. 2021;17(12):4755-60. https://doi.org/10.1080/21645515.2021.1985356
  • Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, et.al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. 2021;36(21):e153. https://doi.org/10.3346/jkms.2021.36.e153
  • Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10:1428. https://doi.org/10.3390/jcm10071428
  • Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et.al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39-51. https://doi.org/10.1016/S1473-3099(20)30831-8
  • Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, et.al. Adverse events in healthcare workers after the first dose of ChAdox1 Ncov-19 Or BNT162b2 mRNA Covid-19 vaccination: a single center experience. J Korean Med Sci. 2021;36(14):e107. https://doi.org/10.3346/jkms.2021.36.e107
  • Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et.al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979-93. https://doi.org/10.1016/S0140-6736(20)32466-1
  • World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, Vaxzevria, SII Covishield): interim guidance. 2021.
  • Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376-81. https://doi.org/10.1016/j.ijid.2021.04.047